Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7561183 | 1.00 | HCAR3 (0.33) | HCAR3HCAR2BACE1CYP3A4 | |
| SCHEMBL13054806 | 0.86 | HCAR3 (0.34) | HCAR3HCAR2BACE1CYP3A4 | |
| SCHEMBL13054435 | 0.86 | CYP3A4 (0.33) | HCAR3HCAR2BACE1CYP3A4 | |
| SCHEMBL7544662 | 0.86 | CYP3A4 (0.33) | HCAR3HCAR2BACE1CYP3A4 | |
| SCHEMBL7563234 | 0.86 | HCAR3 (0.34) | HCAR3HCAR2BACE1CYP3A4 | |
| SCHEMBL7543693 | 0.84 | HCAR3 (0.31) | HCAR3HCAR2BACE1CYP3A4 | |
| SCHEMBL7564234 | 0.83 | BACE1 (0.33) | HCAR3HCAR2BACE1CYP3A4 | |
| SCHEMBL8212784 | 0.83 | BACE1 (0.33) | HCAR3HCAR2BACE1CYP3A4 | |
| SCHEMBL13054334 | 0.81 | BACE1 (0.32) | BACE1CYP3A4 | |
| SCHEMBL7542103 | 0.81 | BACE1 (0.32) | BACE1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
| WO-2008103351-A2 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | HCAR3 1751/4885HCAR2 2333/4885BACE1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.